Sugi Predict

Sugi Predict / Compounds / SCHEMBL3435779

SCHEMBL3435779

SCHEMBL3435779

Cc1ccc2n[nH]c(=O)n2c1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SCN5A Q14524 1/20 0.48
▸ NOTUM Q6P988 10/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ PARP1 P09874 1/20 0.41
▸ COMT P21964 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ CHEK1 O14757 1/20 0.38
▸ PARP10 Q53GL7 1/20 0.37
▸ PRMT5 O14744 1/20 0.37
▸ WDR77 Q9BQA1 1/20 0.37
▸ GLA P06280 1/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10203097 0.86 SCN5A (0.61) SCN5ANOTUMSMN1; SMN2KDM4ECHEK1
SCHEMBL18632544 0.78 SCN5A (0.47) SCN5ANOTUMCHEK1PARP10
SCHEMBL30924244 0.78 SCN5A (0.47) SCN5ANOTUMCHEK1PARP10GAA
SCHEMBL20772490 0.77 SCN5A (0.51) SCN5ANOTUMPRMT5WDR77
SCHEMBL252266 0.77 SCN5A (0.48) SCN5ANOTUMPARP1KDM4ECHEK1
SCHEMBL17403215 0.77 TDP1 (0.47) SCN5ANOTUMCHEK1
SCHEMBL406976 0.77 SCN5A (0.48) SCN5ANOTUMCHEK1
SCHEMBL16154734 0.77 SCN5A (0.48) SCN5ANOTUMPARP1KDM4E
SCHEMBL20772418 0.74 CHEK1 (0.46) SCN5ANOTUMCHEK1
SCHEMBL20773134 0.73 SCN5A (0.48) SCN5ANOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024097355-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS VICINITAS THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
US-11690378-B2 Substituted pyridines as noxious arthropod control agents SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-07-04 — — US disclosed
US-20230167068-A1 BENZOPYRAZOLE COMPOUND MEDSHINE DISCOVERY INC. (CN) 2023-06-01 — — US disclosed
US-20230167068-A1 BENZOPYRAZOLE COMPOUND MEDSHINE DISCOVERY INC. (CN) 2023-06-01 — — US disclosed
EP-3419971-B1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2022-04-20 — — EP disclosed
EP-3954679-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS Gilead Sciences, Inc. (US) 2022-02-16 — — EP disclosed
WO-2021262990-A1 CAPSID INHIBITORS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2021-12-30 — — WO disclosed
WO-2021136429-A1 BENZOPYRAZOLE COMPOUND 南京明德新药研发有限公司 2021-07-08 — — WO disclosed
WO-2019043635-A1 D-AMINO ACID OXIDASE ACTIVITY INHIBITING COMPOUNDS RICHTER GEDEON NYRT. (HU) 2019-03-07 — — WO disclosed
EP-2961742-B1 AMIDE COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES INC (US) 2018-08-01 — — EP disclosed
WO-2017144633-A1 GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2017-08-31 — — WO disclosed
US-20170081324-A1 Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 — — US disclosed
US-20170000788-A1 Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-01-05 — — US disclosed
US-9359351-B2 Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease F. HOFFMANN-LA ROCHE AG (CH) 2016-06-07 — — US disclosed
WO-2016033243-A9 ANTIRETROVIRAL AGENTS GILEAD SCIENCES, INC. (US) 2016-05-19 — — WO disclosed
WO-2016005330-A1 DIHYDROPYRIDOPYRAZINE-1,8-DIONES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF VIRAL DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2016-01-14 — — WO disclosed
US-20160002227-A1 CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE HOFFMANN LA ROCHE (CH) 2016-01-07 — — US disclosed
US-20140303164-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2014-10-09 — — US disclosed
WO-2014134566-A2 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-09-04 — — WO disclosed
WO-2012003392-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. (US) 2012-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11690378-B2 Substituted pyridines as noxious arthropod control agents COX6C, C5, COX6B1 SCN5A 1578/4885NOTUM 2729/4885SMN1; SMN2 2016/4885
US-20230167068-A1 BENZOPYRAZOLE COMPOUND ABCB1, CYP3A43, CYP3A5 SCN5A 464/4885NOTUM 544/4885SMN1; SMN2 2414/4885
US-20170000788-A1 Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease MME, CAPRIN1, XPNPEP1 SCN5A 2372/4885NOTUM 924/4885SMN1; SMN2 4160/4885
US-20160002227-A1 CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE MME, CAPRIN1, XPNPEP1 SCN5A 2372/4885NOTUM 924/4885SMN1; SMN2 4160/4885
US-20170081324-A1 Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease MAPT, TPMT, TTR SCN5A 1331/4885NOTUM 1088/4885SMN1; SMN2 689/4885
US-20140303164-A1 THERAPEUTIC COMPOUNDS HAVCR2, SARS1, G6PD SCN5A 3435/4885NOTUM 1713/4885SMN1; SMN2 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.